Kill the profit motive and you'll kill (most, not all) of the innovative new drugs.
Kill the profit motive and you'll kill (most, not all) of the innovative new drugs.
It would be irrelevant that pharma companies benefit more from perpetual treatment if public research was a more effective balance against that. If pharma doesn't pursue a cure, and a cure is conceivable, then it would behoove academics to pursue it (as the acclaim, and hopefully financial incentive they'd receive would easily motivate them). However, due to the competition for public funding, people are less likely to go down an expensive and time consuming path like that. They're much more likely to pursue incremental discoveries that lead to continued funding rather than bet the farm on a longshot.
The main problem, in my opinion, is that there simply isn't enough science funding.
Unfortunately, there is another side of this coin-- mental health. I believe that currently the problem with the profit motive which you identified is actively harming further research and development of effective cures. Cynically, the biotech companies want to make money, and psychopharmaceuticals are the ultimate cash cow as things are currently. A diagnosis of depression or ADHD means that they have a life-long customer. Thus, in order to maintain these customers buying the drugs at high prices, they must re-invent their cash cow drugs with minor changes in time with the patent cycle. There is no incentive to develop a cure, specifically because the system can be gamed in a very profitable way by rolling over patents and offering bandaid solutions.
Of course not. The alternative is to make the research a public-supported effort. We can hire more scientists with the same amount of money since it isn't being lost to executives or shareholders. Second, all of their information would be open source, which would accelerate advances. Third, drugs don't have to be prioritized by what makes sense from a monetary standpoint and instead can be prioritized from a health standpoint.
The total spend by pharma and biotech? The best number I could find is from PhRMA (a group of the largest pharma companies, but not all of them) and they spend $49B.
Says something about priorities, I guess.
Pork barrel spending based on how many congressional districts the contractor can parcel out work to, irrespective of whether there is a need for the thing being purchased, or whether it cost-effectively meets the need, or whether there's even any realistic chance that the thing being purchased will ever have any practical application?